Archive for the ‘Gene Therapy Research’ Category

Public release date: 14-Oct-2013 [ | E-mail | Share ]

Contact: Aeron Haworth aeron.haworth@manchester.ac.uk 44-161-275-8387 University of Manchester

The Manchester Academic Health Science Centre (MAHSC) has formed a partnership with the Peking University Health Sciences Centre to establish an international centre of excellence in genetic medicine.

The new Peking-Manchester Centre for Genomic Medicine, announced by British Chancellor George Osborne in Beijing today (Monday), will comprise three separate but interdependent research facilities the International Centre for Rare Diseases, the Centre for Cancer Genetics, and the Joint Clinical Trials Facility.

MAHSC's involvement is being led by the Manchester Centre for Genomic Medicine, an integrated centre bringing together University of Manchester researchers and Central Manchester NHS Foundation Trust's clinical services, to form a world leader in genetic and genomic medicine for research into inherited diseases and delivery of services to families with inherited disorders.

Speaking at Peking University, the Chancellor, who is in China to promote UK business and encourage Chinese investors to choose Britain, said: "I am delighted to announce here the establishment of a new partnership between Peking University and Manchester University in the UK with the creation of a new joint centre for genomic medicine. Here, in the oldest and most prestigious medical school in China, let us work together on the medicines of tomorrow.

"This partnership will, I hope, give even more of you the chance to come to Britain and to study there. We already have 130,000 Chinese students, like you, studying in Britain I want more of you to come There is no limit to the number of Chinese [students] who can study in Britain."

Dean and Vice-President of the University of Manchester's Faculty of Medical and Human Sciences and Director of MAHSC, Professor Ian Jacobs, who is participating in the government-led visit, said: "This is an exciting partnership between MAHSC and our colleagues in Beijing. It will lead to important health and research benefits in the rapidly developing field of genetics to benefit the people of both countries as well as having a global impact. The planned work will draw on populations of up to 50 million individuals to harness next-generation genetic technology for patient benefit.

"The joint venture will contribute to the further development of the research strength of the Manchester Academic Health Science Centre and advance Manchester's international reputation as a world leader in personalised cancer medicine, while improving care and diagnosis for many people here and in China."

The Peking University Health Sciences Centre (PUHSC) is the oldest Western medical school in China, ranked first in the country for research and training. As part of the collaboration, six senior geneticists from the Manchester Centre for Genomic Medicine will travel to Beijing this week to deliver a training course for more than 300 health professionals and scientists at PUHSC.

Read the original here:
UK Chancellor announces Sino-British health partnership

Carilion Clinic Living: Breast Cancer and Genetics
Thuy Vu, a certified genetics counselor with Carilion Clinic in Roanoke, Va. discusses how your family medical history can play a role in the risk for breast...

By: Carilion Clinic

See more here:
Carilion Clinic Living: Breast Cancer and Genetics - Video

Race and Genetics in Bodybuilding- Response to Nick Wright
Responding to racial comments made regarding bodybuilding and athletics based on my experience as a bi-racial person. OFFICIAL SITE: http://yungmuscle.com/ F...

By: YungMuscleOfficialTV

Go here to read the rest:
Race and Genetics in Bodybuilding- Response to Nick Wright - Video

SOUR SECRET - DNA Genetics - Voyagers Coffeeshop - Amsterdam Weed Review
http://andrew.pyrah.net Thanks for watching! COMMENT and LIKE if you enjoyed the video and SUBSCRIBE to see my new videos as they are released. This video is...

By: Andrew Pyrah

View original post here:
SOUR SECRET - DNA Genetics - Voyagers Coffeeshop - Amsterdam Weed Review - Video

GENETICS Australia says shareholders will benefit from the sale of its retail and services businesses.

GA sold these operations in Gippsland to Herd Improvement Co-operative yesterday and its Western District operations to Northern Herd Development Co-operative.

It said the sales would achieve benefits similar to a proposed merger with HICO and provide a "necessary rationalisation of the herd improvement sector".

Genetics Australia chairman Ross Gordon said a merger between HICO and GA was not off the table, but the costs and time involved, especially in the tough dairying climate, forced the co-operatives to look at another path to rationalisation.

"We had to cut some serious cost down," Mr Gordon said.

"What we were doing with the merger would take quite a bit more money ... and there wasn't any guarantee we would get it over the line and then meet the thresholds (for tax).

"There was a potential $100,000 bill for capital gains tax and there is not that sort of money in the industry ... to give away."

The move ensures a lab to test herd recording results remains in each Victorian dairy region, while GA will return to its original business of production, import and marketing of semen and related products.

"It's a good win for shareholders, they still get choices and there will be a lab in each region," Mr Gordon said.

"It's consolidation of the herd improvement industry with the two key co-operatives."

More here:
Genetics Australia sells off divisions

Analyzing Is Magic: The Problem With Pegasi Genetics
Something that I noticed. Thought I would share. With apologies to Tom Petty. Anyway, what do you think of this! Comments and questions below! ... OC Faces: ...

By: ILoveKimPossibleAlot

Here is the original post:
Analyzing Is Magic: The Problem With Pegasi Genetics - Video

ORCHARD, Texas, Oct. 15, 2013 (GLOBE NEWSWIRE) -- Exclusive Genetics, a leader and innovator in the bucking bull industry, is out-of-the-gate with exciting investment opportunities for enthusiasts nationwide. No ranch, no truck, no trailer, no experience necessary - bucking bulls are not just for ranchers and cowboys anymore. With the explosive growth of this traditionally western lifestyle sport, the bucking bull industry is now capturing the attention of a completely new group of customers - business owners, corporate executives and professionals. Exclusive Genetics gives these new thrill-seekers the ability to experience high quality, high payout events and at the same time enjoy great hospitality and fellowship.

With investors including several CEOs of major corporations and the Manager of a Major League Baseball team, Exclusive Genetics caters to the needs of the first-time client by developing events that fit the investors' interests. The cornerstone of EG's program is the Million Dollar Bucking Bull Championship for 2-year-old bulls. The event's $1,000,000 payout and $500,000 check to the top bull makes the event the most lucrative and highly respected in the entire bucking bull world.

Businessman, rancher, bucking bull trainer and CEO of Exclusive Genetics, Billy Jaynes developed a marketing concept six years ago that was based on the horse racing industry.

Jaynes comments that, "The bucking bull industry, since its inception was a closed society of rancher, farmers and cowboys. I saw the opportunity to open investment to mainstream fans through the horse racing model. The vast majority of horse owners are not involved in the maintenance of the animal. They hire a trainer to care for the horse and get the enjoyment and financial rewards of the sport by watching their animal participate in competition. It's the same with owning bucking bulls, EG's operations is setup where an owner does not have to maintain the bull. Both investors and sportsman are finding this style of industry participation to be very appealing and a unique investment."

Investment in the breeding and development of young bulls to compete in 2-year-old futurities is skyrocketing. A Bucking Bull Futurity is a competition held for two year-old bulls that do not have a rider on their back. A mechanical weight is placed on the bulls back and is judged on kick, spin, intensity and the perceived difficulty to ride.

What makes the Million Dollar Bucking Bull Championship all the more interesting and exciting is that the vast amount of bucking bull owners are neither traditional cowboys nor breeders, but mainstream investors who don't possess a hauling trailer or ranch.

Jaynes said that "In the turbulent current world of Wall Street, livestock may provide an additional avenue to seek return." He added, "It's amazing to think that one of our investors who mostly consist of businesspeople, fans and professionals will in just a few months walk away with the $500,000 winner's share of the Million Dollar Bucking Bull Championship purse. We did the training work, now it's time for them to root!"

The Million Dollar Bucking Bull Championship will be held in December during the National Finals Rodeo in Las Vegas with $1,000,000 in prize money. It will offer the largest purse for any bucking bull event in the history of the sport. Investment in the purchase of bulls for the 2013 event was so strong that investors are currently buying into the 2015 edition of the Futurity.

The Million Dollar Bucking Bull Championship and all of EG's Bucking Bull Games have become the third largest event to take place in Las Vegas during the Wrangler National Finals Rodeo, held over a 10 day period each December. EG's Bucking Bulls Games will payout in excess of over $1,300,000 in 2013. Only the National Finals Rodeo and World Series of Team Roping offer larger payouts during that period.

To learn more about Exclusive Genetics' Million Dollar Bucking Bull Championship or other investment opportunities, contact Jeff Bressler at jeff@exclusivegenetics.com or visit http://www.exclusivegenetics.com.

See more here:
Bucking Bull Industry Leader, Exclusive Genetics, Offers Opportunities to Non-Traditional Investors Who Will Reap ...

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) announced today that it will report its third quarter 2013 financial results on Tuesday, November 5, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Tuesday, November 5, 2013

1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

REPLAY access

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The companys lead product, ADCETRIS (brentuximab vedotin), is an ADC that, in collaboration with Millennium: the Takeda Oncology Company, has been approved for two indications in 35 countries, including the U.S., European Union and Canada. Additionally, ADCETRIS is being evaluated broadly in more than 20 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-75, ASG-22ME, SGN-CD19A, SGN-CD33A, SGN-LIV1A and ASG-15ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at http://www.seattlegenetics.com.

More:
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2013 Financial Results on November 5 ...

Dublin, Oct. 14, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/bq6p7v/bioinformatics) has announced the addition of the "Global Bioinformatics Market Report 2013-2017" report to their offering.

Based on the use of bioinformatics, the various sectors covered in this report are medicine, agriculture, environment, animal, forensic, academics, and others (homeland security and defense, law-enforcement groups, bio-weapon creation, antibiotic resistance, and evolutionary biotechnology). The medical sector accounted for a lions share of the bioinformatics market in 2012. The medical sector has been further classified as molecular medicine, gene therapy, drug discovery and development, clinical diagnostics, and reproductive biotechnology.

The bioinformatics market, by products and services, has been classified as knowledge management tools, platforms, and services. These segments are integral components of application areas such genomics, proteomics, and other life-science research, and are used for the acquisition, development, management, analysis, and integration of huge amounts of data generated during biological research. Knowledge management tools dominated the bioinformatics market in 2012, followed by platforms and services. Knowledge management tools are majorly used by researchers to handle large volumes of heterogeneous information and to integrate them with existing knowledge repositories.

Segments in the bioinformatics application market are genomics, proteomics, chemoinformatics, molecular phylogenetics, metabolomics, transcriptomics, and others (glycomics, cytomics, physiomics and interactomics). Genomics contributes the highest to the bioinformatics market; it is poised to grow at a high CAGR from 2012 to 2017. The application of bioinformatics in genomics is driven by growing pharmacogenomics applications for the discovery of new drugs and characterization of older drugs, development of new bioinformatics tools to handle large sets of data generated through genomics research, and decreasing cost of DNA sequencing. Metabolomics is the fastest-growing application area due to developments in analytical instruments that enable profiling of metabolites with high throughput and accuracy.

North America accounted for the largest market share of the bioinformatics market, followed by Europe, in 2012. This is attributed by an increasing demand for bioinformatics in genomics and proteomics research, technological advancements, growing use of bioinformatics tools in the drug discovery process, and presence of a large number of market players. However, other regions such as Asian and Latin American countries represent emerging markets, owing to a rise in research outsourcing by pharmaceutical giants, increasing number of Contract Research Organizations (CROs), rise in public and private sector investment, and growing industry -academia partnerships.

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Market Overview

4 Global Bioinformatics Market, By Sectors

Here is the original post:
Global Bioinformatics Market Report 2013-2017

Santa Fe, New Mexico (PRWEB) October 15, 2013

October 15, 2013, Santa Fe, New Mexico

The Estrogen Gene Test Co. and General Genetics Corporation are pleased to announce the launch of a saliva-based test that can identify polymorphisms in all of the key estrogen metabolism genes.

Decades of research from top universities and institutions around the world reveal in studies that while mutations on single estrogen metabolism genes do not seem to raise the risk of breast cancer; women who possess two or more mutations are at greater risk have from a 2.7 to 13 fold increased risk of breast cancer than women without mutations.

80% of all breast cancer diagnosis is to women with no family history. EstroGeneTM allows physicians to pinpoint patients at greater risk and clinically intervene to improve estrogen metabolism function. In turn, this may lower their breast cancer risk regardless of their previous or current estrogen exposure, breast cancer status or fertility stage.

EstroGeneTM is recommended for all women and girls, however critical populations to test include women with past, present or future exposure to estrogen-based medications such as hormone replacement therapy, bio-identical hormones and in-vitro fertilization. Women treated for estrogen positive breast cancer, women with a family history of breast cancer and women with severe peri-menopausal symptoms should also test.

Since the first results of the landmark Womens Health Initiative study published in 2002, which highlighted the two-and-a-half times increased risk of breast cancer to women taking Hormone Replacement Therapy, physicians have struggled with the complexity of relieving menopausal or peri-menopausal symptoms and improving fertility. On the one hand, estrogen based medications may help relieve severe symptoms or promote fertility or allow egg retrieval. On the other hand, breast cancer, as well as other risks, are well known. Physicians no longer need to operate within the 2.5 times increased risk bell curve but can assess each patients risk individually and actively work to mitigate that risk by improving estrogen metabolism function.

Dr. Joseph Veltmann, Ph.D., Chief Scientific Officer for the Estrogen Gene Test Company, Founder of the Institute for Individualized Medicine and one of the worlds leading Nutrigenomic experts has been following 350 high risk women with mutation on the genes in the EstroGeneTM for the past 10 years. Out of the 350 women followed, none have developed the breast cancer disease or had a recurrence by following gene specific protocols to improve estrogen metabolism function. Dr. Veltmann commented, Since the vast majority of women have no family history of breast cancer, the increased availability of this test can allow women to take more meaningful control over their health. It may remove some of the mystery behind a breast cancer diagnosis and its prevention.

The Estrogen Gene Test Company has partnered with Clinical Testing Laboratory, a division of General Genetics Corporation, as its laboratory partner in the processing of Estrogene. Clinical Testing Laboratories is CLIA-certified and performs a wide variety of genetic analysis, including pharmacogenomics, genotyping and other sequencing services for partners around the world.

About Estrogen Gene Test Company The Estrogen Gene Test Co., http://www.estrogengenetest.com, is an outgrowth of the efforts of the Hormonal Cancer Foundation, http://www.hormonalcancer.org, to promote estrogen metabolism genetic testing before, during and after the use of estrogen medications or for women with estrogen receptor positive breast cancer. EGT is strongly committed to genetic testing to prevent breast cancer and is asking all women taking the test to participate in a Hormonal Cancer Foundation longitudinal study examining the outcome of changing gene expression to prevent breast cancer.

Original post:
The Estrogen Gene Test Co. and General Genetics Corporation Announce the Launch of EstroGeneTM, for Breast Cancer ...

Distinguished cardiologist brings extensive experience in novel approaches for treating patients with cardiovascular disease

Raleigh, N.C., Oct. 14, 2013 - INC Research, a therapeutically focused global clinical research organization (CRO) with a Trusted Process for delivering reliable results, today announced the appointment of Martin Sullivan, MD, as Executive Medical Director, Cardiovascular Medicine. Dr. Sullivan will leverage his strong therapeutic insight into clinical trials involving cardiovascular drugs and devices for a wide range of conditions to provide hands-on medical management of the Company`s cardiology trials and to drive clinical development globally in this key therapeutic area.

"The prevalence of cardiovascular diseases provides significant opportunity for the development of new therapies to improve the health and overall wellbeing of many patients worldwide," said Sally Osmond, Executive Vice President and General Manager, Cardiovascular and Endocrinology Clinical Development at INC Research. "Marty is a highly respected cardiologist with extensive experience both in practice and in clinical development, having implemented more than 100 clinical research projects. We`re thrilled to have a thought leader of his caliber to lead development of these complex trials."

Board-certified in both internal medicine and cardiovascular diseases, Dr. Sullivan brings more than 25 years of experience in medical practice and clinical research to INC Research. Prior to joining the Company, he worked as a research consultant specializing in noninvasive cardiology. He earned his medical degree at The Ohio State University and received his post-graduate cardiology training at Duke University where he remained on faculty, later becoming an Associate Professor of Medicine. Dr. Sullivan has had a long and distinguished career at a variety of institutions, including stints as the Director of the Duke Center for Integrative Medicine; Director of Cardiovascular Research at the Heartland Regional Medical Center in St. Joseph`s, Missouri; and a Senior Research Consultant in the Division of Cardiology at the University of North Carolina. For his contributions to cardiovascular research, Dr. Sullivan was named an Established Investigator of the American Heart Association.

Dr. Sullivan will present "New Frontiers in Cardiovascular Research: Biologic Therapies - Using stem cells, gene therapy, and growth factors to treat patients with cardiovascular disease," a complimentary webinar, on Wednesday, Oct. 16, at 3 p.m. GMT/10 a.m. EDT. The webinar will cover the current state of research for cardiovascular diseases and will discuss novel approaches in clinical development, such as cell therapies, growth factors and gene therapies that are being used to regrow cells, repair damage and improve cardiovascular health without surgery. Click here to register.

About INC Research INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit http://www.incresearch.com or follow us at @inc_research.

Contact: Lori Dorer, Media +1 (513) 345-1685

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: INC RESEARCH, LLC via Thomson Reuters ONE HUG#1735540

Original post:
INC Research Strengthens Cardiovascular Research Capabilities with Appointment of Dr. Martin Sullivan as Executive ...

tzi the Iceman has at least 19 living male relatives in the Austrian Tirol, according to a genetic study into the origins of the people who now inhabit the region.

Scientists from the Institute of Legal Medicine at Innsbruck Medical University analyzed DNA samples taken from 3,700 blood donors in the Tyrol region of Austria.

During their study, they discovered that 19 individuals share a particular genetic mutation with the 5,300-year-old mummy, whose full genome was published last year.

PHOTOS: Iceman Mummy 20 Yrs On: Mysteries Remain

These men and the Iceman had the same ancestors, Walther Parson, the forensic scientist who carried out the study, told the Austrian Press Agency.

The researchers focused on parts of the human DNA which are generally inherited unchanged.

In men it is the Y chromosomes and in females the mitochondria. Eventual changes arise due to mutations, which are then inherited further, Parson explained.

People with the same mutations are categorized in haplogroups. Designed with letters, haplogroups allow researchers to trace early migratory routes since they are often associated with defined populations and geographical regions.

Indeed, tzis haplogroup is very rare in Europe.

The Iceman had the halogroup G, sub category G-L91. In our research we found another 19 people with this genetic group and subgroup, Parson said.

Read the original:
Living Relatives of Iceman Mummy Found

Why Science? Plant Genetics
Explore Research at the University of Florida: Matias Kirst, an associate professor in quantitative genetics at the University of Florida, discusses how his ...

By: FloridaMuseum

Visit link:
Why Science? Plant Genetics - Video

NEW YORK, Oct. 14, 2013 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf of investors who purchased Atossa Genetics, Inc. ("Atossa" or the "Company") (ATOS) stock between November 8, 2012 and October 4, 2013.

For more information, click here: http://zlk.9nl.com/atossa-genetics-atos.

The Complaint alleges that throughout the Class Period defendants made false and misleading statements and/or failed to disclose the following: a) that the Company failed to submit an additional 510(k) notification to obtain necessary FDA clearance as it made material changes to the Nipple Aspirate Fluid specimen collection process; b) that the Company improperly marketed its device by using certain promotional claims to market its ForeCYTE Breast Health Test and the MASCT device; and c) that the Company was in violation of FDA Good Manufacturing Practices regulations.

On October 4, 2013, Atossa announced a voluntary recall of its ForeCYTE Test, including a recall of the MASCT System Kit and Patient Sample Kit. The recall commenced to address concerns raised in a February 2013 warning letter issued by the U.S. Food and Drug Administration.

If you suffered a loss in Atossa you have until December 9, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/atossa-genetics-atos.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

More here:
ATOSSA GENETICS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Against Atossa Genetics, Inc ...

Stem Cell Therapy in India for Osteoarthritis
Completely bedridden patient have started joint movements after transplantation of autologous stem cells intra thically and thhough IV. His stem cell transpl...

By: StemRx BioScience

Read more from the original source:
Stem Cell Therapy in India for Osteoarthritis - Video

Stem Cell Therapy Process: Murphy the Irish Wolfhound
Murphy is a 6 year old Irish Wolfhound who is both a service dog and a therapy dog. When he tore his ACL and then fell and fractured his pelvis, we had only ...

By: wesbroAZ

Read the rest here:
Stem Cell Therapy Process: Murphy the Irish Wolfhound - Video

Mathew Blurton Jones - New Hope: Stem Cell Therapy in Alzheimer #39;s Disease
"New Hope: Stem Cell Therapy in Alzheimer #39;s Disease" Mathew Blurton-Jones, Ph.D. -- University of California, Irvine 24th Annual Southern California Alzheime...

By: UCITLTC

Read more:
Mathew Blurton Jones - New Hope: Stem Cell Therapy in Alzheimer's Disease - Video

Public release date: 13-Oct-2013 [ | E-mail | Share ]

Contact: Karen Mallet km463@georgetown.edu Georgetown University Medical Center

WASHINGTON An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer. Their findings are reported online today in Nature Genetics.

The investigators identified STAG2 as one of the most commonly mutated genes in bladder cancer, particularly in tumors that do not spread. The finding suggests that checking the status of the gene may help identify patients who might do unusually well following cancer treatment, says the study's senior investigator, cancer geneticist Todd Waldman, MD, PhD, a professor of oncology at Georgetown Lombardi.

"Most bladder cancers are superficial tumors that have not spread to other parts of the body, and can therefore be easily treated and cured. However, a small fraction of these superficial tumors will recur and metastasize even after treatment," he says.

Because clinicians have been unable to definitively identify those potentially lethal cancers, all bladder cancers patients after surgery to remove tumors must undergo frequent endoscopic examinations of their bladder to look for signs of recurrence, says Waldman. This procedure, called cystoscopy, can be uncomfortable and is expensive.

"Our data show that STAG2 is one of the earliest initiating gene mutations in 30-40 percent of superficial or 'papillary-type' bladder tumors, and that these tumors are unlikely to recur," says David Solomon, MD, PhD, a lead author on the study. Solomon is a graduate of the Georgetown MD/PhD program and is currently a pathology resident at the University of California, San Francisco.

"We have developed a simple test for pathologists to easily assess the STAG2 status of these tumors, and are currently performing a larger study to determine if this test should enter routine clinical use for predicting the likelihood that a superficial bladder cancer will recur," Solomon says.

For the study, the researchers examined 2,214 human tumors from virtually all sites of the human body for STAG2 inactivation and found that STAG2 was most commonly inactivated in bladder cancer, the fifth most common human cancer. In follow up work, they found that 36 percent of low risk bladder cancers those that never invaded the bladder muscle or progressed had mutated STAG2. That suggests that testing the STAG2 status of the cancer could help guide clinical care, Waldman says. "A positive STAG2 mutation could mean that patient is at lower risk of recurrence."

The researchers also found that 16 percent of the bladder cancers that did spread, or metastasize, had mutated STAG2.

Read more:
In a surprise finding, gene mutation found linked to low-risk bladder cancer

Genetic Engineering and Islam

By: Mahmoud Gamil

More here:
Genetic Engineering and Islam - Video

SALT LAKE CITY, Oct. 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) today announced that results from a verification study showed the Myriad myPath(TM) Melanoma test effectively differentiated malignant melanoma from benign skin lesions. The clinically-actionable information provided by myPath Melanoma will empower healthcare providers with objective data and improve the diagnosis of patients with melanoma. Myriad presented these data at the American Society of Dermatopathology Annual Meeting on Oct. 13, 2013.

The verification study evaluated a 23-gene panel designed to differentiate malignant melanoma from benign skin lesions. The study analyzed 464 skin biopsy samples including 254 samples representing melanomas from all major subtypes including superficial spreading, lentigo maligna melanoma, acral, nodular and desmoplastic lesions. Using this set of patient samples, the myPath Melanoma test demonstrated high sensitivity of 89 percent and specificity of 93 percent at differentiating malignant melanoma from benign skin lesions.

"The data from this large cohort showed that this test is highly accurate, relative to expert dermatopathologic review, at differentiating malignant melanoma from benign skin lesions," said Sancy Leachman, M.D., Ph.D, chair of the Department of Dermatology in the Oregon Health & Science University (OHSU) School of Medicine and director of the Melanoma Research Program at the Knight Cancer Institute. "The diagnosis of melanoma by conventional methods often is subjective, and this test provides objective data which could make it an extremely valuable and useful diagnostic tool to help save patients' lives."

Melanoma is the most serious type of skin cancer. According to the American Cancer Society statistics, about 76,000 new melanomas are diagnosed each year, and more than 9,000 people die from melanoma annually. Each year in the United States, there are approximately two million skin biopsies performed specifically for the diagnosis of melanoma. Approximately 14 percent or 280,000 biopsies are classified as indeterminate, which means the dermatopathologist cannot confidently determine whether the cells are benign or malignant.

"Patients and physicians with an indeterminate biopsy result face the challenging clinical question of whether to treat the lesion as melanoma or risk not treating a potentially fatal cancer," Loren Clarke, M.D., vice president of Medical Affairs of Dermatology at Myriad. "Late-stage melanoma has a five-year survival rate of 15 percent compared to early-stage melanomas that have five-year survival rates of about 90 percent. The ability to accurately diagnose and treat melanoma early on is critical to obtaining favorable long-term clinical outcomes."

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website at: http://www.myriad.com and our social media channels: Twitter and Facebook.

Myriad, the Myriad logo and myPath are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to myPath Melanoma providing clinically-actionable information that will empower healthcare providers with objective data and improve the diagnosis of patients with melanoma; myPath Melanoma providing objective data which could make it an extremely valuable and useful diagnostic tool to help save patients' lives; and the Company's strategic directives under the caption "About Myriad Genetics". These "forward-looking statements" are management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; risks related to changes in the governmental or private insurers reimbursement levels for our tests; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to increased competition and the development of new competing tests and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and companion diagnostic services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Read this article:
Myriad's myPath(TM) Melanoma Test is Highly Effective in Verification Study

SEATTLE, WA--(Marketwired - Oct 14, 2013) - Atossa Genetics Inc. (NASDAQ: ATOS), The Breast Health Company, announced today that Gregory L. Weaver has joined the Company's Board of Directors and has been appointed a member of the Audit Committee.

"Greg brings a wealth of financial and operational experience in the Life Sciences industry to Atossa's Board of Directors and Audit Committee, including mergers and acquisitions, licensing transactions, regulatory approvals, and new product launches, as well as strategic planning and cost control efforts," said Steven C. Quay, Chairman, President & CEO. "Greg's experience will be invaluable to the Board and to management as we continue to build the Company."

Weaver has built a successful career in executive financial and operations management serving as CFO of small to mid-cap public and private biotechnology companies. He currently serves as Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary of Fibrocell Science, Inc. Prior to joining Fibrocell Science in September 2013, he served as CFO with the following public companies: Celsion Corp., Poniard Pharmaceuticals, Sirna Therapeutics (acquired by Merck), Nastech Pharmaceuticals, and ILEX Oncology (acquired by Genzyme), and venture funded firms Talyst, Inc. and Prism Technologies. In addition, Greg served as a director and audit committee chairman of Celsion from 2005-2011, as a director with the Washington State WBBA, and has consulted with other biotech companies throughout his career. Greg began his career as a Certified Public Accountant with Arthur Andersen. He has a Master of Business Administration from Boston College and Bachelor of Science from Trinity University.

"I appreciate the opportunity to join the Board of Directors of Atossa Genetics at this important juncture," commented Weaver. "Atossa has the potential to make a significant contribution toward women's breast health and I look forward to the future success of the Company."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. is focused on the commercialization of patented, diagnostic medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests. The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information please visit http://www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this Press Release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory clearances needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors, estimated future expenses and cash needs, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Follow this link:
Gregory L. Weaver Joins Atossa Genetics' Board of Directors

Stem Cell therapy in India for ischemic heart disease (ISD)
ISD can be treated with stem cell therapy at StemRx Bioscience Solutions. In case of above patient we have seen drastic improvement is heart functioning.

By: StemRx BioScience

Continue reading here:
Stem Cell therapy in India for ischemic heart disease (ISD) - Video

Panama before last stem cell therapy treatment

By: Johanna Smith

View original post here:
Panama before last stem cell therapy treatment - Video

The Genetics of Warfarin (Coumadin) Response

By: CoriellInstitute

Original post:
The Genetics of Warfarin (Coumadin) Response - Video

Stem cell therapy in India for Avascular Necrosis (AVN)
Avascular necrosis can be completely treated with stem cell therapy. Stem cell therapy provided at StemRx Bioscience solutions is strong alternative option f...

By: StemRx BioScience

Read this article:
Stem cell therapy in India for Avascular Necrosis (AVN) - Video